Figure 2From: Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusChanges in CD20+ B cells. Median percentage change from baseline in CD20+ B cells in (a) single-dose cohorts and (b) double-dose cohorts. Arrows indicate time of belimumab administration.Back to article page